As PD-L1 expression is commonly used as a criterion for determining whether cancer patients should undergo ICI treatment, we examined the correlation between PD-L1/PD-1 expression levels, risk scores, and the expression of EPGN, LCN10, and TP73. This evidence concerns the gene LCN10 and cancer.